| Company Name: | Cambrex Corporation | | Ticker Symbol: | CBM | | | WWW Address: | www.cambrex.com | | CEO: | Steven M. Klosk | | No. of Employees: | 856 | | Common Issue Type: | CS | | Business Description: | The Company mainly provides products and services worldwide to pharmaceutical companies and generic drug companies.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 5.93 |  0.12 | 5.92 | 5.94 | 5.83 | 6.06 | 5.71 | 29390 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 173.7 | 29.3 | 1.65 | 0.27 | 0.00 | 14.2 | 0.0 | 7.22 - 1.48 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 5.81 | $ | | PE Ratio - LTM | 14.2 | |
| Market Capitalisation | 170.1 | mil |
| Latest Shares Outstanding | 29.3 | mil |
| Earnings pS (EPS) | 0.27 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 291,154 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 28.6 | mil |
| Float as % of Shares Outstanding | 97.8 | % |
| Foreign Sales | 163 | mil |
| Domestic Sales | 87 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 15.50 | % |
| Research & Devlopment (R&D) as % of Revenue | 3.10 | % |
| Gross Profit Margin | 29.1 | % |
| EBITDA Margin | 10.5 | % |
| Pre-Tax Profit Margin | 8.2 | % |
| Assets Turnover | 0.7 | % |
| Return on Assets (ROA) | 3.4 | % |
| Return on Equity (ROE) | 11.6 | % |
| Return on Capital Invested (ROCI) | 5.3 | % |
| Current Ratio | 3.0 | |
| Leverage Ratio (Assets/Equity) | 3.4 | |
| Interest Cover | 5.4 | |
| Total Debt/Equity (Gearing Ratio) | 1.18 | |
| LT Debt/Total Capital | 54.0 | % |
| Working Capital pS | 3.47 | $ |
| Cash pS | 1.55 | $ |
| Book-Value pS | 3.60 | $ |
| Tangible Book-Value pS | 2.34 | $ |
| Cash Flow pS | 1.09 | $ |
| Free Cash Flow pS | 0.39 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 1.61 | |
| Price/Tangible Book Ratio | 2.48 | |
| Price/Cash Flow | 5.3 | |
| Price/Free Cash Flow | 15.0 | |
| P/E as % of Industry Group | 63.0 | % |
| P/E as % of Sector Segment | 10.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Dividend Declared Date | 04/09/2007 |
| Dividend Ex-Date | 05/03/2007 |
| Dividend Record Date | 04/19/2007 |
| Dividend Pay Date | 05/02/2007 |
| Dividend Amount | 14000 |
| Type of Payment | Cash Payment |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 94.7 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 38.0 |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -0.9 | 98 | 1,056 | 2,838 |
| 4 Weeks | 6.73 | 5.58 | 6.00 | -3.2 | 91 | 1,116 | 18,969 |
| 13 Weeks | 7.22 | 5.37 | 5.52 | 5.3 | 98 | 1,339 | 81,675 |
| 26 Weeks | 7.22 | 3.65 | 3.60 | 61.4 | 134 | 1,372 | 171,538 |
| 52 Weeks | 7.22 | 1.48 | 3.48 | 67.0 | 135 | 1,602 | 398,886 |
| YTD | 7.22 | 1.48 | - | 25.8 | 103 | 1,556 | 353,114 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 5.94 | 6.07 | 6.38 | 5.14 | 4.39 | 1.65 | 1.45 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | -13.47 | 73.9 | -18.42 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | -7.55 | NA | -12.07 |
| R&D | -19.59 | NA | -29.52 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -4.5 | -3.3 | -1.3 |
| Earnings % | 48.2 | 5.9 | -96.2 |
| EPS % | 45.2 | 0.0 | -96.3 |
| EPS $ | 0.14 | 0.00 | -7.03 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 21.81 |
| Current Ratio | 2.1 |
| Quick Ratio (Acid Test) | 1.1 |
| Liquidity Ratio (Cash) | 0.50 |
| Receivables Turnover | 6.1 |
| Average Collection Period | 59 |
| Working Capital/Equity | 99.5 |
| Working Capital pS | 2.55 |
| Cash-Flow pS | 0.99 |
| Free Cash-Flow pS | -0.88 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 1.57 |
| Financial Leverage Ratio (Assets/Equity) | 4.6 |
| Debt Ratio | 78.1 |
| Total Debt/Equity (Gearing Ratio) | 1.66 |
| LT Debt/Equity | 1.66 |
| LT Debt/Capital Invested | 101.5 |
| LT Debt/Total Liabilities | 46.5 |
| Interest Cover | 4.4 |
| Interest/Capital Invested | 1.62 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 2.93 |
| Tobin's Q Ratio | 0.50 |
| Current P/E Ratio - LTM | 14.20 |
| Enterprise Value (EV)/EBITDA | 16.75 |
| Enterprise Value (EV)/Free Cash Flow | -15.08 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 2.48 |
| Price/Book Ratio - LTM | 1.61 |
| Price/Cash Flow Ratio | 5.3 |
| Price/Free Cash Flow Ratio - LTM | 15.0 |
| Price/Sales Ratio | 0.71 |
| P/E Ratio (1 month ago) - LTM | 16.5 |
| P/E Ratio (26 weeks ago) - LTM | 12.9 |
| P/E Ratio (52 weeks ago) - LTM | 11.6 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 63.0 |
| P/E as % of Sector Segment | 10.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 12.3 |
| PER SHARE FIGURES |
| LT Debt pS | 4.24 |
| Current Liabilities pS | 2.22 |
| Tangible Book Value pS - LTM | 2.34 |
| Book Value pS - LTM | 3.60 |
| Capital Invested pS | 6.78 |
| Cash pS - LTM | 1.55 |
| Cash Flow pS - LTM | 1.09 |
| Free Cash Flow pS - LTM | 0.39 |
| Earnings pS (EPS) | 0.27 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -10.30 |
| Free Cash Flow Margin 5YEAR AVG | -36.41 |
| Net Profit Margin | 3.2 |
| Net Profit Margin - 5YEAR AVRG. | 2.7 |
| Equity Productivity | 3.33 |
| Return on Equity (ROE) | 10.6 |
| Return on Equity (ROE) - 5YEAR AVRG. | 4.7 |
| Capital Invested Productivity | 1.26 |
| Return on Capital Invested (ROCI) | 4.0 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 2.7 |
| Assets Productivity | 0.70 |
| Return on Assets (ROA) | 2.3 |
| Return on Assets (ROA) - 5YEAR AVRG. | 1.8 |
| Gross Profit Margin | 29.1 |
| Gross Profit Margin - 5YEAR AVRG. | 43.1 |
| EBITDA Margin - LTM | 10.5 |
| EBIT Margin - LTM | 10.1 |
| Pre-Tax Profit Margin | 6.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | -3.9 |
| Effective Tax Rate | 47.1 |
| Effective Tax Rate - 5YEAR AVRG. | -17.4 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 179 |
| Revenue per Employee | 291,154 |
| Net Income per Employee | 9,263 |
| Average Collection Period | 53 |
| Receivables Turnover | 6.1 |
| Day's Inventory Turnover Ratio | 126 |
| Inventory Turnover | 2.9 |
| Inventory/Sales | 24.5 |
| Accounts Payble/Sales | 7.90 |
| Assets/Revenue | 1.43 |
| Net Working Capital Turnover | 3.35 |
| Fixed Assets Turnover | 1.23 |
| Total Assets Turnover | 0.7 |
| Revenue per $ Cash | 7.66 |
| Revenue per $ Plant | 1.54 |
| Revenue per $ Common Equity | 3.33 |
| Revenue per $ Capital Invested | 1.26 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 16.9 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 22.6 |
| Research & Devlopment (R&D) as % of Revenue | 3.0 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 3.0 |
|
|  
|
| |
 |  |